Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation

Author： Katz Matthew  

Publisher： Springer Publishing Company

ISSN： 1068-9265

Source： Annals of Surgical Oncology, Vol.17, Iss.7, 2010-07, pp. : 1794-1801

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer

By Kondo Naru  

Annals of Surgical Oncology, Vol. 17, Iss. 9, 2010-09 ,pp. : 2321-2329

Springer Publishing Company

Access to resources Recommend Favorite

RE: CA 19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Preoperative Therapy

By Bold Richard  

Annals of Surgical Oncology, Vol. 20, Iss. 7, 2013-07 ,pp. : 2108-2110

Springer Publishing Company

Access to resources Recommend Favorite

CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy

By Hartwig Werner   Strobel Oliver   Hinz Ulf   Fritz Stefan   Hackert Thilo   Roth Constanze   Büchler Markus   Werner Jens  

Annals of Surgical Oncology, Vol. 20, Iss. 7, 2013-07 ,pp. : 2188-2196

Springer Publishing Company

Access to resources Recommend Favorite

Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer

By Irmscher Sabrina  

Annals of Surgical Oncology, Vol. 15, Iss. 7, 2008-07 ,pp. : 2059-2060

Springer Publishing Company

Access to resources Recommend Favorite

Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer

By Palmer Daniel  

Annals of Surgical Oncology, Vol. 15, Iss. 7, 2008-07 ,pp. : 2061-2061

Springer Publishing Company

Access to resources Recommend Favorite